We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 wild-type ALRN-6924 Merkel cell carcinoma predicted - sensitive detail...
RB1 loss LY3295668 Merkel cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02036476 Phase II Cabozantinib Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT02155647 Phase II Avelumab Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Completed USA | ITA | FRA | ESP | DEU | AUS 1
NCT02267603 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Completed USA 0
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Completed USA | NLD | GBR | FRA | ESP | DEU | BEL 4
NCT02514824 Phase Ib/II Sapanisertib MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Completed USA 0
NCT02584829 Phase Ib/II IFN-B Avelumab Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Completed USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03071406 Phase II Ipilimumab + Nivolumab Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Active, not recruiting USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Active, not recruiting POL | NZL | FRA | ESP | AUS 4
NCT03228667 Phase II Docetaxel + Nivolumab + Nogapendekin alfa inbakicept Docetaxel + Nogapendekin alfa inbakicept + Pembrolizumab Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab Durvalumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Avelumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Atezolizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Nivolumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Durvalumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Avelumab + Nogapendekin alfa inbakicept Atezolizumab + Nogapendekin alfa inbakicept QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors Recruiting USA 0
NCT03271372 Phase III Avelumab Adjuvant Avelumab in Merkel Cell Cancer (ADAM) Active, not recruiting USA 0
NCT03304639 Phase II Pembrolizumab Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Active, not recruiting USA 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Terminated USA 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT03599713 Phase II Retifanlimab A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma Completed USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03712605 Phase III Pembrolizumab Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Active, not recruiting USA 0
NCT03747484 Phase Ib/II Avelumab + FH-MCVA2TCR Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Terminated USA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03783078 Phase III Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Completed USA | SWE | NZL | ITA | FRA | ESP | CAN | AUS 0
NCT03787602 Phase Ib/II Avelumab + KRT-232 KRT-232 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BRA | AUS 1
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Completed USA 0
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Active, not recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03853317 Phase II Avelumab + haNK cells + Nogapendekin alfa inbakicept Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy. Terminated USA 0
NCT03901573 Phase Ib/II Atezolizumab + NT-I7 High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Terminated USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Terminated USA | FRA | BEL | AUS 1
NCT03988647 Phase II Pembrolizumab Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA 0
NCT04160065 Phase I IFx-Hu2.0 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Completed USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04261855 Phase Ib/II Avelumab Avelumab + lutetium Lu 177 dotatate Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM) Recruiting AUS 0
NCT04291885 Phase II Avelumab Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) Active, not recruiting NZL | AUS 0
NCT04349436 Phase Ib/II RP1 A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS) Recruiting USA 0
NCT04393753 Phase II Avelumab + Domatinostat Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2) Completed NLD | ITA | FRA | ESP | DEU | BEL 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04590781 Phase Ib/II Pembrolizumab + XmAb18087 XmAb18087 Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer Terminated USA 0
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04792073 Phase II Avelumab Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Recruiting USA 0
NCT04819373 Phase II EIK1001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04869137 Phase II Lenvatinib + Pembrolizumab Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma Active, not recruiting USA 0
NCT04874831 Phase II Avelumab + Domatinostat Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) Withdrawn 0
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Terminated USA 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04916002 Phase II Cemiplimab + Vidutolimod CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer Terminated USA | AUS 0
NCT04975152 Phase I Cemiplimab Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05120271 Phase Ib/II BOXR1030 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) Recruiting USA | GBR 0
NCT05199272 Phase Ib/II 23ME-00610 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies Active, not recruiting USA | CAN 0
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Recruiting ITA | FRA | ESP 0
NCT05422781 Phase I ITI-3000 Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) Completed USA 0
NCT05496036 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) Recruiting USA 0
NCT05583708 Phase II lutetium Lu 177 dotatate + Pembrolizumab Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT) Suspended USA 0
NCT05594290 Phase II Cisplatin + Etoposide + Retifanlimab Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (MERCURY) Recruiting ITA 0
NCT05859074 Phase I MQ710 + Pembrolizumab MQ710 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Active, not recruiting USA 0
NCT05896839 Phase Ib/II Ipilimumab + Nivolumab + Prednisone + Sirolimus Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ESP | AUS 0
NCT05947500 Phase II M1774 Avelumab + M1774 Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Recruiting USA | CAN 0
NCT06014086 Phase I PH-762 Intratumoral PH-762 for Cutaneous Carcinoma Recruiting USA 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06056895 Phase II INCAGN02385 + INCAGN02390 + Retifanlimab Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC) Active, not recruiting USA 0
NCT06086288 Phase II Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naive Advanced meRkel Cell cArcinoma (MCC) (PANDORA) Not yet recruiting ITA 0
NCT06151236 Phase II Nivolumab + Relatlimab Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Recruiting AUS 0
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06814496 Phase Ib/II Tarlatamab Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Not yet recruiting USA 0